for intravenous use Initial U.S. Approval: 2011
Yervoy (ipilimumab) is a kinase inhibitor indicated for the treatment of advanced (unresectable or metastatic) melanoma.
Facts about Ipilimumab Injection
Trade Name: On Request
Packaging: injection, for intravenous use
Strength: Injection: 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL) in a single-use vial.
DISEASE INDICATIONS-Urothelial Carcinoma, Skin Cancer
MEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA), Pharmaceuticals and Medical Devices Agency (PMDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “Ipilimumab Injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For Ipilimumab Injection
Approved accessible "Ipilimumab Injection"
Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for:
- Treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older).
- Adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
- Treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma, in combination with nivolumab.
Ipilimumab was approved by the U.S. Food and Drug Administration (FDA) in March 2011, to treat people with late-stage melanoma that has spread or cannot be removed by surgery.
How To access Ipilimumab Injection?
Yervoy (Ipilimumab Injection) for intravenous use Initial U.S. Approval: 2011
To access Ipilimumab Injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa